Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- DLTH +19.4%, WGO +6.7%, VKTX +5.6%, FDX +2.8%, SLW +2.8%, HQY +2.7%, AYA +1.6%, MDP +1.1%, PBR +0.9%
Select metals/mining names showing strength:
- X +1.3%, AG +1.2%, AKS +1.1%, SBGL +0.8%, HMY +0.8%, ABX +0.7%, CLF+0.6%, AU +0.5%, RIO +0.5%
Other news:
- UNXL +23.7% (enters into a long-term agreement w/ a 'major U.S.-based PC maker' to supply XTouch touch screen sensors on a multiple year basis)
- IDXG +12.2% (continued strength after closing near highs)
- MBRX +12.1% (granted orphan designation by the FDA for liposomal annamycin for the treatment of acute myeloid leukemia)
- BEBE +8.7% (modestly rebounding)
- ACHN +4.4% (announces that the U.S. Patent and Trademark Office has issued the first U.S. Patent to Achillion resulting from its complement factor D research program), CMCM +2.2% (continued strength)
- OPK +1.4% (confirms orphan drug designation from the FDA for oligonucleotide-based AntagoNAT for the treatment of Dravet Syndrome)
- SNAP +1.1% (initiated with a Buy at Drexel Hamilton; $30 tgt)
- VRX +0.7% (closed its previously announced refinancing transactions; extends maturities of term loan debt to 2022 and provides increased operational flexibility)
- SHPG +0.7% (granted Fast Track designation for recombinant ADAMTS13)
Analyst comments:
- URBN +1.5% (upgraded to Overweight from Sector Weight at KeyBanc Capital Mkts)
- SNAP +1.2% (initiated with a Buy at Drexel Hamilton)
- BBVA +1% (upgraded to Overweight from Equal Weight at Barclays)
- LC +0.8% (upgraded to Neutral from Underperform at Wedbush)